e-SPACE Cardio-Renal-Metabolic 2022: On-demand

Published: 11 April 2022

  • Views:

    Views Icon 791

  • Likes:

    Heart Icon 0

Overview

Full programme

  • Views:

    Views Icon 791

  • Likes:

    Heart Icon 0

Overview

e-SPACE CARDIO-RENAL-METABOLIC 2022, held on 4-6 March 2022, was the second edition of the global online conference on cardio renal metabolic diseases.

 

The organisers, under the direction of a world-renowned scientific committee, brought together leading experts in cardiology, nephrology, and diabetology to share clinical practice strategies in treating the inter-related diseases now affecting hundreds of millions people worldwide.

 

This on-demand version of the event comprises:

 

  • Presentations and discussions with leading experts
  • Evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity
  • Insight to SLGT2i, GLP-1RA and other emerging therapies
  • 'Meet the Expert' sessions

 

e-SPACE Cardio-Renal-Metabolic 2022 was supported by the following companies:

Series overview

Part 1

Meet the Expert: IgA nephropathy: current optimal management

1 session
Meet the Expert: IgA nephropathy: current optimal management Watch now

Part 2

Session 1: The new KDIGO guidelines

5 sessions
Welcome and introduction Watch now
1.1: BP in CKD Guidelines Watch now
1.2: Diabetes and CKD GL Watch now
1.3: General management of the nephrotic syndrome Watch now
Panel Discussion Watch now

Part 3

Industry Session: Iron deficiency in heart failure and kidney disease: interdisciplinary crosstalk

Supported by an unrestricted educational grant from Vifor Pharma
4 sessions
Welcome and Introduction Watch now
Management of iron deficiency in heart failure: new evidence, new guidelines Watch now
Iron deficiency in chronic kidney disease: why iron matters beyond anaemia Watch now
Interactive panel discussion Watch now

Part 4

Session 2: Recent CV guidelines and treatment algorithms

5 sessions
Introduction Watch now
2.1: The new ESC HF guidelines Watch now
2.2: Personalised management Watch now
2.3: Preventive cardiology Watch now
Panel Discussion Watch now

Part 5

Meet the Experts: NAFLD/NASH as a metabolic disease: improving patients outcomes

1 session
Meet the Experts: NAFLD/NASH as a metabolic disease: improving patients outcomes Watch now

Part 6

Session 3: Management of SGLT2 a practical approach

5 sessions
Introduction Watch now
3.1: Focus on diabetology Watch now
3.2: Focus on cardiology Watch now
3.3: Focus on nephrology Watch now
Panel Discussion Watch now

Part 7

Meet the Experts: The meaning of Hemoglobin A1C for the nephrologist and the cardiologist

4 sessions
Introduction Watch now
The meaning of Hemoglobin A1C for the nephrologist Watch now
The meaning of Hemoglobin A1C for the cardiologist Watch now
Panel discussion Watch now

Part 8

Session 4: GLP-1RA and cardio-metabolic disease in diabetes

5 sessions
Introduction Watch now
4.1: GLP-1RA and CVD in diabetes Watch now
4.2: GLP-1 RA and kidney disease in diabetes Watch now
4.3: Obesity and cardio-metabolic disease: Role of GLP-1RA Watch now
Panel discussion Watch now

Part 9

Industry Session: SGLT2 inhibitors in cardio-renal-metabolic disease: optimizing the patient's journey

Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance
6 sessions
Welcome and introduction Watch now
Cardio-renal-metabolic disease in a nutshell Watch now
SGLT2 inhibitors in patients with type 2 diabetes and comorbidities Watch now
SGLT2 inhibitors in patients with heart failure and comorbidities Watch now
SGLT2 inhibitors in patients with chronic kidney disease and comorbidities Watch now
Panel discussion Watch now

Part 10

Session 5: HFpEF: tackling a multidisciplinary problem

6 sessions
Introduction Watch now
5.1: Diagnosis, pathophysiology, epidemiology Watch now
5.2: Diabetes Watch now
5.3: In chronic kidney disease Watch now
5.4: Management with new drugs and devices (CCM, Intra atrial shunts and Cardiomems) Watch now
Panel discussion Watch now

Part 11

Meet the Experts: CKD progression in CVD screening and follow-up

4 sessions
Introduction Watch now
Mechanism of disease interplay between CVD and CKD Watch now
The use of SGLT2is in patients with CKD and CVD with and without diabetes Watch now
Panel discussion Watch now

Part 12

Meet the Experts: CV, mortality & kidney outcomes with GLP-1 AR in patients with T2DM

1 session
Meet the Experts: CV, mortality & kidney outcomes with GLP-1 AR in patients with T2DM Watch now

Part 13

Session 6: New trial update in cardiology

6 sessions
Introduction Watch now
6.1: EMPEROR-Preserved Watch now
6.2: Preserved HF Watch now
6.3: Dronedarone in AF management: A 2022 update Watch now
6.4: Upcoming trials in 2022 (Deliver, Diamond, Iron Man) Watch now
Panel discussion Watch now

Part 14

Meet the Experts: The HF Diabetic patient with CKD: optimizing care for a high-risk group

1 session
Meet the Experts: The HF Diabetic patient with CKD: optimizing care for a high-risk group Watch now

Part 15

Meet the Expert: Multidisciplinary management of cardio-renal-metabolic disease: focus on the kidney

5 sessions
Introduction Watch now
The case for early identification, risk stratification and treatment of CKD Watch now
Protecting the kidney and the heart: the cardiologist's perspective Watch now
Identifying high-risk patients: the primary care physician's perspective Watch now
Panel discussion Watch now

Part 16

Session 8: Sarcopenia, frailty malnutrition and cachexia

5 sessions
Welcome and introduction Watch now
8.1: Cachexia in CV disease Watch now
8.2: Cachexia in CKD Watch now
8.3: Muscle wasting in stroke Watch now
Panel discussion Watch now

Part 17

Meet the Expert: HIF PHI: What do we know and don't know in 2022

1 session
Meet the Expert: HIF PHI: What do we know and don't know in 2022 Watch now

Part 18

Session 9: The cardio-kidney interaction: relevance to diabetes

6 sessions
Introduction Watch now
9.1: Diabetes and CVD today Watch now
9.2: Diabetes and kidney today Watch now
9.3: The cross-talk between kidney and heart Watch now
9.4: Therapeutic solution Watch now
Panel discussion Watch now

Part 19

Industry Session: SGLT2 inhibition in the comorbid CKD patient

Satellite Symposium supported by an unrestricted educational grant from AstraZeneca
2 sessions
SGLT2 inhibition in the comorbid CKD patient Watch now
Panel discussion Watch now

Part 20

Session 10: Why and how to screen for heart failure and kidney disease in diabetes

5 sessions
Introduction Watch now
10.1: Screening of kidney disease Watch now
10.2: Screening of heart failure Watch now
10.3: Horizons opened by the screening Watch now
Panel discussion Watch now

Part 21

Meet the Expert: SGLT2 inhibitors in heart failure: Improving outcomes across the spectrum of the disease

4 sessions
Welcome and introduction Watch now
New developments in SGLT2 inhibitor use in HFrEF and HFpEF Watch now
Implementing guidelines in clinical practice Watch now
Panel discussion Watch now

Part 22

Session 11: SGLT2 inhibition in clinical practice

6 sessions
Introduction Watch now
In ambulatory HFrEF and HFpEF Watch now
When to start after acute decompensation Watch now
Improving QoL and symptoms Watch now
The case of acute MI Watch now
Panel discussion Watch now

Part 23

Meet the Expert: The meaning of eGFR for the cardiologists and diabetologist

1 session
Meet the Expert: The meaning of eGFR for the cardiologists and diabetologist Watch now

Part 24

Session 12: Managing obesity in the CRM setting

6 sessions
Introduction Watch now
Practical issues of managing weight loss in CRM disease: the therapeutic options Watch now
Managing weight loss in CRM disease: the nephrologist's perspective Watch now
Managing weight loss in CRM disease: the diabetologist's perspective Watch now
Managing weight loss in CRM disease: the cardiologists' perspective Watch now
Panel discussion Watch now

Part 25

Meet the Experts: Personalized care of patients with heart failure: hyperkalemia as a barrier to optimal medical therapy

3 sessions
Welcome and introduction Watch now
Overcoming barriers to guideline-mandated medical therapy in heart failure the role of long-term potassium control Watch now
Interactive panel discussion Watch now

Part 26

Meet the Expert: SGLT2, the statin of the 21st century

1 session
Meet the Expert: SGLT2, the statin of the 21st century Watch now

Part 27

Session 13: New trial update in nephrology

6 sessions
Introduction Watch now
DAPA CKD: Key lessons from subgroup analyses Watch now
FIDELIO/FIGARO DKD Watch now
FIDELITY - Main lessons including subgroup analyses Watch now
Chlortalidone in CKD stage 4: A new look at an old drug Watch now
Panel discussion Watch now

Part 28

Meet the Experts: Reducing the risk of cardiovascular events for patients with CKD and T2DM: new treatment options

5 sessions
Introduction Watch now
Screening and diagnosis best practices Watch now
Primary care perspective and challenges Watch now
Reducing CV risks and new treatment options: case discussion Watch now
Panel discussion Watch now

Part 29

Session 14: Telemedicine in CRM

5 sessions
Introduction Watch now
Digital technologies in CV disease Watch now
Remote monitoring of HF Watch now
Telemedicine in CKD from a cardiologist's perspective Watch now
Panel discussion Watch now

Part 30

Session 15: New drugs, new hopes and sometimes risks

5 sessions
Introduction Watch now
Ascend D and ASCEND ND Watch now
The moving field of drug nephrotoxicity Watch now
The role of new potassium binding agents in cardio-renal medicine Watch now
Panel discussion Watch now

Part 31

Meet the Expert: Management of worsening HF

1 session
Meet the Expert: Management of worsening HF Watch now

Part 32

Session 16: Harmonising the gluco-and cardio-centric management of diabetes

5 sessions
Introduction Watch now
Cardio-centric approach Watch now
Gluco-centric approach Watch now
Combination therapy as starting option Watch now
Panel discussion Watch now

Faculty Biographies

Sydney Tang

Sydney Tang

Professor Sydney Tang is currently Chair of Renal Medicine and Yu Professor in Nephrology at the University of Hong Kong. He underwent training in nephrology in Hong Kong and in basic research at King’s College London, UK, and the University of Washington, USA.

Professor Tang’s research interests revolve around pathogenetic mechanisms underlying diabetic and proteinuric kidney disease, and the treatment of immunoglobulin A nephropathy.

Professor Tang is the President-elect of the Asian Pacific Society of Nephrology,an Executive Committee member of Kidney Disease: Improving Global Outcomes, Deputy Chair of the Continuing Medical Education Committee, member of the Saving Young Lives Committee and Education Work Group and an N&E Asia Regional Board member of the International Society of Nephrology, and an International Honorary Member of the Japanese Society of Nephrology. He is a past Chairman of the Hong Kong Society of Nephrology and serves the Hong Kong…

View full profile